AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21873560 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 145
Study 21873560 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 145
Study 18474762 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for home-based walking and strength exercise (EXC)
Number of subjects: 224
Study 16813178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Taichong (LR 3) and Hegu (LI 4)
Number of subjects: 102
Study 16813178 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of heloperidol
Number of subjects: 102
Study 16813178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 102
Study 12694789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver
Number of subjects: 20
Study 12694789 — intervention group
Group type: COMPARATOR
Intervention: Cardiotomy suction
Number of subjects: 20
Study 10740947 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment designed to reduce risk of relapse
Number of subjects: 0
Study 10740947 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 8602566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.2Fr catheter
Number of subjects: 300
Study 8602566 — intervention group
Group type: EXPERIMENTAL
Intervention: 6Fr catheter
Number of subjects: 300
Study 8602566 — intervention group
Group type: EXPERIMENTAL
Intervention: 7Fr catheter
Number of subjects: 300
Study 8602566 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending physician
Number of subjects: 300
Study 8602566 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular fellow
Number of subjects: 300
Study 8602566 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller catheters
Number of subjects: 300
Study 8602566 — intervention group
Group type: EXPERIMENTAL
Intervention: All catheter sizes
Number of subjects: 300
Study 1533504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (salbutamol and ipratropium bromide)
Number of subjects: 0
Study 1533504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 2413818 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 2413818 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Number of subjects: 0
Study 2413818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31576916 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity aerobic exercise plus standard medical treatment
Number of subjects: 46
Study 31576916 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment without exercise intervention
Number of subjects: 46
Study 28636795 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for smoking cessation
Number of subjects: 144
Study 27415795 — intervention group
Group type: EXPERIMENTAL
Intervention: AndoSanTM
Number of subjects: 50
Study 27415795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24602005 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral bolus dose of 6,8,10,3',5'‐(13)C5‐C3G
Number of subjects: 8
Study 22677568 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia fiber, psyllium fiber, and fructose (AFPFF) 16.8 g daily
Number of subjects: 100
Study 22677568 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol 3350 with electrolytes (PEG+E) 0.5 g/kg daily
Number of subjects: 100
Study 19802519 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 70
Study 19802519 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave coagulation (MC)
Number of subjects: 70
Study 19802519 — intervention group
Group type: COMPARATOR
Intervention: Control group (EBL alone)
Number of subjects: 70
Study 17964516 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg every 6 hours for 5 doses)
Number of subjects: 22
Study 17964516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16234004 — intervention group
Group type: COMPARATOR
Intervention: Octreotide monotherapy
Number of subjects: 105
Study 16234004 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide plus interferon-alpha
Number of subjects: 105
Study 16234004 — intervention group
Group type: EXPERIMENTAL
Intervention: Not randomized due to stable disease
Number of subjects: 105
Study 12196491 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete liquid nutrition supplement containing energy, vitamins, and minerals, including enhanced levels of antioxidants
Number of subjects: 19
Study 12196491 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo drink
Number of subjects: 19
Study 12196491 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete liquid nutrition supplement
Number of subjects: 19
Study 12196491 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete liquid nutrition supplement and Noncaloric placebo drink
Number of subjects: 19
Study 10196075 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a three-mobile serial list
Number of subjects: 0
Study 10196075 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a five-mobile list
Number of subjects: 0
Study 10196075 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivation (priming) test
Number of subjects: 0
Study 10196075 — intervention group
Group type: EXPERIMENTAL
Intervention: Precued with one list member
Number of subjects: 0
Study 7778530 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 7.5 mg twice daily, increased to 15 mg twice daily after 2 weeks
Number of subjects: 198
Study 7778530 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 2.5 mg twice daily, increased to 5 mg twice daily after 2 weeks
Number of subjects: 198
Study 7778530 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 15 mg twice daily
Number of subjects: 198
Study 7778530 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg twice daily
Number of subjects: 198
Study 2317057 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position group
Number of subjects: 40
Study 2317057 — intervention group
Group type: COMPARATOR
Intervention: Recumbent position group
Number of subjects: 40
Study 6938020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Stilboestrol
Number of subjects: 0
Study 6938020 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate
Number of subjects: 0
Study 6938020 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 0
Study 6938020 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol
Number of subjects: 0
Study 6938020 — intervention group
Group type: COMPARATOR
Intervention: Estracyt
Number of subjects: 0
Study 6938020 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 0
Study 6938020 — intervention group
Group type: COMPARATOR
Intervention: Procarbazine
Number of subjects: 0
Study 31679902 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (12 sessions, 2 sessions a week for 6 weeks)
Number of subjects: 112
Study 31679902 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 112
Study 31722536 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy plus guideline-directed medical therapy
Number of subjects: 0
Study 31722536 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy alone
Number of subjects: 0
Study 27666136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 670/0.75
Number of subjects: 120
Study 27666136 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 120
Study 26371354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisters Tell Others and Revive Yourself (STORY)
Number of subjects: 168
Study 26371354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 23337300 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC)
Number of subjects: 213
Study 23337300 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol and fluticasone via separate inhalers (Sal/FP)
Number of subjects: 213
Study 23337300 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SFC and Sal/FP
Number of subjects: 213
Study 21324094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER (20-80 mg/day)
Number of subjects: 875
Study 21324094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 21324094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER
Number of subjects: 875
Study 21324094 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 875
Study 19204571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 11
Study 19204571 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 11
Study 19204571 — intervention group
Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 11
Study 17301567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive VCT (on-site counselling and rapid testing)
Number of subjects: 3146
Study 17301567 — intervention group
Group type: COMPARATOR
Intervention: Standard VCT (pre-paid vouchers to an external provider)
Number of subjects: 3146
Study 17301567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (intensive and standard VCT)
Number of subjects: 3146
Study 15337700 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 0
Study 15337700 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 11606875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 831
Study 10367415 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum levels of prostate specific antigen
Number of subjects: 0
Study 10367415 — intervention group
Group type: COMPARATOR
Intervention: Screening for prostate cancer
Number of subjects: 0
Study 10367415 — intervention group
Group type: COMPARATOR
Intervention: Radical treatment of localized disease
Number of subjects: 0
Study 8006249 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina-guided medical therapy
Number of subjects: 618
Study 8006249 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina-guided plus ambulatory ECG ischemia-guided medical therapy
Number of subjects: 618
Study 8006249 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (coronary angioplasty or bypass surgery)
Number of subjects: 618
Study 8006249 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem plus isosorbide dinitrate
Number of subjects: 618
Study 8006249 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol plus nifedipine
Number of subjects: 618
Study 2679833 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 24
Study 2679833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1234491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine (50 mg)
Number of subjects: 0
Study 1234491 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (5 mg)
Number of subjects: 0
Study 1234491 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (2.5 mg)
Number of subjects: 0
Study 31641701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevia snacks
Number of subjects: 271
Study 31641701 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol snacks
Number of subjects: 271
Study 31641701 — intervention group
Group type: COMPARATOR
Intervention: Sugar snacks
Number of subjects: 271
Study 30082554 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar trastuzumab (study trastuzumab)
Number of subjects: 106
Study 30082554 — intervention group
Group type: COMPARATOR
Intervention: Reference trastuzumab
Number of subjects: 106
Study 30082554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (study and reference trastuzumab)
Number of subjects: 106
Study 26028131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity shave margins resected (shave group)
Number of subjects: 235
Study 26028131 — intervention group
Group type: COMPARATOR
Intervention: No cavity shave margins resected (no-shave group)
Number of subjects: 235
Study 23581458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation of V. cinerea for 3 months
Number of subjects: 48
Study 23581458 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 48
Study 23581458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation of V. cinerea
Number of subjects: 48
Study 23581458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21812735 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 to 400 mg/d
Number of subjects: 360
Study 21812735 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine ER
Number of subjects: 360
Study 21812735 — intervention group
Group type: COMPARATOR
Intervention: Desvenlafaxine
Number of subjects: 360
Study 19804822 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) therapy
Number of subjects: 129
Study 19804822 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-therapy with topiramate (TPR)
Number of subjects: 129
Study 19804822 — intervention group
Group type: EXPERIMENTAL
Intervention: Model validation in a separate set of 24 patients
Number of subjects: 129
Study 16434675 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate therapy
Number of subjects: 82
Study 16434675 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta (control)
Number of subjects: 82
Study 12783400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 143
Study 12783400 — intervention group
Group type: COMPARATOR
Intervention: Microemulsion cyclosporin A (micro‐CsA)
Number of subjects: 143
Study 10981544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared meal plan (CCNW)
Number of subjects: 158
Study 10981544 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet (SSD)
Number of subjects: 158
Study 9185645 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m sestamibi scintigraphy
Number of subjects: 0
Study 9185645 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 0
Study 9185645 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine infusion with technetium-99m sestamibi
Number of subjects: 0
Study 9185645 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine infusion with echocardiography
Number of subjects: 0
Study 8359165 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 62
Study 8359165 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 62
Study 3534315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone for 3 days before and on the day of chemotherapy
Number of subjects: 67
Study 3534315 — intervention group
Group type: COMPARATOR
Intervention: Cyclic intravenous chemotherapy with aminoglutethimide and hydrocortisone
Number of subjects: 67
Study 3534315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone
Number of subjects: 67
Study 3534315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 28581317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day training and a refresher session 3 months later
Number of subjects: 148
Study 28581317 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no training)
Number of subjects: 148
Study 26669917 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary outpatient program (3.5‐h multidisciplinary group‐based educational program followed by individual consultations)
Number of subjects: 391
Study 26669917 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary outpatient program
Number of subjects: 391
Study 26669917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 391
Study 24909860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambivalent friends
Number of subjects: 104
Study 24909860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambivalent feedback
Number of subjects: 104
Study 24909860 — intervention group
Group type: COMPARATOR
Intervention: Supportive friends
Number of subjects: 104
Study 22015818 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 μg/d
Number of subjects: 48
Study 22015818 — intervention group
Group type: COMPARATOR
Intervention: alendronate 10 mg/d
Number of subjects: 48
Study 20549236 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (standard dosage schedule)
Number of subjects: 0
Study 20549236 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (increased concentration during the first week and third week)
Number of subjects: 0
Study 17933486 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment
Number of subjects: 166
Study 15882230 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing technique with scores after brushing and scores before brushing included as a covariate
Number of subjects: 0
Study 15882230 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing technique with differences in scores before and after brushing, including scores before brushing as a covariate
Number of subjects: 0
Study 15882230 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing technique without including scores before brushing as a covariate
Number of subjects: 0
Study 12858617 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week theory-based physical activity program (treatment group, n = 29)
Number of subjects: 58
Study 12858617 — intervention group
Group type: COMPARATOR
Intervention: Traditionally structured exercise program (control group, n = 29)
Number of subjects: 58
Study 11789167 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghua aerosol (SHA)
Number of subjects: 276
Study 11789167 — intervention group
Group type: COMPARATOR
Intervention: Shuanghuanglian aerosol (SHLA)
Number of subjects: 276
Study 8712867 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 30
Study 8712867 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 30
Study 8712867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 1676212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical salicylic acid
Number of subjects: 0
Study 1676212 — intervention group
Group type: COMPARATOR
Intervention: Emollients without salicylic acid
Number of subjects: 0
Study 6226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (0.025%)
Number of subjects: 34
Study 6226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone‐17‐valerate (0.1%)
Number of subjects: 34
Study 6226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone‐17,21‐dipropionate (0.05%)
Number of subjects: 34
Study 6226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone‐17,21‐dipropionate (in psoriasis)
Number of subjects: 34
Study 6226490 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (in psoriasis)
Number of subjects: 34
Study 31112576 — intervention group
Group type: EXPERIMENTAL
Intervention: Straddling cardiopulmonary resuscitation
Number of subjects: 0
Study 31112576 — intervention group
Group type: COMPARATOR
Intervention: Walking cardiopulmonary resuscitation
Number of subjects: 0
Study 30008159 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR)
Number of subjects: 139
Study 30008159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study 27006452 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy
Number of subjects: 60
Study 27006452 — intervention group
Group type: COMPARATOR
Intervention: Self‐guided therapy
Number of subjects: 60
Study 24977347 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine 50 mg
Number of subjects: 60
Study 24977347 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine 400 mg
Number of subjects: 60
Study 24977347 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 60
Study 22162481 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Number of subjects: 51
Study 22162481 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/wk LB03002 for 36 months (n=13)
Number of subjects: 51
Study 22162481 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Number of subjects: 51
Study 22162481 — intervention group
Group type: COMPARATOR
Intervention: Daily GH 0.03 mg/kg/d for 24 months, switched to 0.5 mg/kg/wk LB03002 for 12 months (n=12)
Number of subjects: 51
Study 20412107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D-penicillamine (DPA) at 100 mg/kg/dose every 8 hours for 3 days, followed by 50 mg/kg/day for 11 days
Number of subjects: 88
Study 20412107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20412107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D-penicillamine (DPA)
Number of subjects: 88
Study 17660072 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombin (rhThrombin)
Number of subjects: 401
Study 17660072 — intervention group
Group type: COMPARATOR
Intervention: Bovine thrombin
Number of subjects: 401
Study 16177289 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 40,000 U QW
Number of subjects: 358
Study 16177289 — intervention group
Group type: COMPARATOR
Intervention: DARB 200 microg Q2W
Number of subjects: 358
Study 12783702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 510
Study 12783702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 10491347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oximetry with spectral analysis
Number of subjects: 233
Study 10491347 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak amplitude threshold of 0.7%
Number of subjects: 233
Study 10491347 — intervention group
Group type: EXPERIMENTAL
Intervention: r(S) threshold of 0.15
Number of subjects: 233